或 JAK3。 参考资料： [1]. Bristol Myers Squibb. Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants with Psoriasis (POETYK PSO-1).https://clinicaltrials.gov/ct2/show/NCT03624127. NLM identifier: NCT03624127. [2]. Bristol Myers Squibb. An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants with Moderate-to-Severe Plaque Psoriasis (POETYK-PSO-2).https://clinicaltrials.gov/ct2/show/NCT03611751. NLM identifier: NCT03611751. [3]. Michalek, I. M., Loring, B. & John, S. M. Global report on psoriasis. (2016). Geneva, Switzerland: World Health Organization. [4]. Langley RGB et al. Psoriasis: epidemiology, clinical features, and quality of life.Ann Rheum Dis.2005;64(Suppl II):ii18–ii23. doi: 10.1136/ard.2004.033217. [5]. Pariser et al. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis.J Dermatolog Treat.2015;27(1):19-26. doi: 10.3109/09546634.2015.1044492. [6]. Kimball A.B. et al. Psoriasis: is the impairment to a patient's life cumulative?J Eur Acad Dermatol Venereol.2010 Sep;24(9):989-1004. doi: 10.1111/j.1468-3083.2010.03705. [7]. Menter A et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.J Am Acad Dermatol.2008 May;58(5):826-50. doi: 10.1016/j.jaad.2008.02.039. [8]. Ortonne JP, Prinz JC. Alefacept: a novel and selective biologic agent for the treatment of chronic plaque psoriasis. Eur J Dermatol. 2004 Jan-Feb;14(1):41-5. PMID: 14965795. [9]. National Psoriasis Foundation. Psoriasis Statistics.https://www.psoriasis.org/psoriasis-statistics/. Accessed September 8, 2021. [10]. Griffiths C & Barker J. Pathogenesis and clinical features of psoriasis.Lancet. 2007 Jul 21;370(9583):263-271. doi: 10.1016/S0140-6736(07)61128-3. [11]. Alwan W et al. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine.Clin Exp Rheumatol.Sep-Oct 2015;33(5 Suppl 93):S2-6. [12]. Mahil S, Capon F & Barker J. Update on psoriasis immunopathogenesis and targeted immunotherapy.SeminImmunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. [13]. Horn EJ et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey.J Am Acad Dermatol. 2007;57:957-962. [14]. Armstrong A. et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data.Dermatol Ther (Heidelb).2017 Mar; 7(1): 97–109. [15]. Hrehorow, E et al. (2012). Patients with psoriasis feel stigmatized,Acta Derm Venereol.92(1):67-72. doi:10.2340/00015555-1193. [16]. Armstrong A, Harskamp C & Armstrong E. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies.Nutr Diabetes.2013. Dec 3;2(12):e54. doi: 10.1038/nutd.2012.26. [17]. Dubertret L et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.Br J Dermatol.2006 Oct;155(4):729-36. [18]. Oliveira, M., Rocha, B., & Duarte, G. V. Psoriasis: classical and emerging comorbidities.Anais brasileiros de dermatologia. Jan-Feb2015; 90(1), 9–20. https://doi.org/10.1590/abd1806-4841.20153038. [19]. Neimann A et al. Prevalence of cardiovascular risk factors in patients with psoriasis.J Am Acad Dermatol. 2006;55(5), 829–835. https://doi.org/10.1016/j.jaad.2006.08.040. [20]. Lebwohl MG et al. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Am J Clin Dermatol. 2016 Feb;17(1):87-97. doi: 10.1007/s40257-015-0169-x. [21]. Lebwohl MG et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.J Am Acad Dermatol. 2014 May;70(5):871-81.e1-30. doi: 10.1016/j.jaad.2013.12.018. 来源：金色财经lg...
北美站
